Telix Pharmaceuticals share price (ASX:TLX) closed 6.56% higher at A$11.70 today, capping an impressive month-long recovery that has seen the biotech stock gain 32.35% from recent lows. The rally marks a significant reversal for a company that endured a bruising 57% decline over the past twelve months, though long-term holders can still point to a 170% gain over five years as evidence of the stock’s volatile but ultimately rewarding trajectory.
Clinical and Regulatory Momentum
The recent price momentum appears driven by a confluence of positive clinical developments and renewed regulatory engagement. On March 9, Telix announced encouraging results from Part 1 of its global Phase 3 ProstACT study evaluating TLX591-Tx, a novel radioligand therapy for prostate cancer. The study met its key objectives, demonstrating an acceptable safety profile and sustained tumor uptake across the patient cohort. For a company that has weathered significant regulatory headwinds, the clean clinical readout provided markets with much-needed validation of its therapeutic pipeline.
Days later, on March 15, Telix resubmitted its New Drug Application to the U.S. Food and Drug Administration for TLX101-Px, marketed as Pixclara, an investigational imaging agent for glioma. The resubmission includes additional data addressing prior FDA requests, signaling the company’s commitment to navigating the regulatory pathway despite previous setbacks. This proactive approach has helped restore confidence among market participants who had grown cautious following last year’s regulatory troubles.
The current rally suggests markets are willing to look past historical challenges, at least for now, as clinical progress and regulatory resubmissions demonstrate forward momentum. However, the legal proceedings remain unresolved, and the company continues to face scrutiny over its prior disclosures. The sustainability of this recovery will likely depend on Telix’s ability to secure regulatory approvals, particularly for its resubmitted applications, while successfully defending against ongoing litigation.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Bull Case:
- Positive results from the global Phase 3 ProstACT study for its prostate cancer therapy, TLX591-Tx.
- Resubmission of its New Drug Application for the glioma imaging agent Pixclara to the U.S. FDA.
- Strong recent stock momentum, with a 32.35% surge from recent lows.
Bear Case:
- Ongoing subpoena from the U.S. Securities and Exchange Commission regarding company disclosures.
- Faces multiple securities class action lawsuits alleging misleading statements.
- History of regulatory setbacks, including a Complete Response Letter from the FDA for TLX250-CDx.
- The TLX share price remains down 57% over the past year, indicating significant investor concern and volatility.
For TLX bulls, the 32% monthly gain represents a significant technical reversal, though the shares remain well below its twelve-month highs. The path forward hinges on execution across multiple fronts: advancing clinical programs, clearing regulatory hurdles, and restoring trust with stakeholders who endured last year’s turbulence.
